ArticleJournal of affective disorders2022
Altered brain regional homogeneity is associated with depressive symptoms in COVID-19.
Article in Journal of affective disorders, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 31 citations in OpenAlex.
- Functional brain abnormalities in post COVID-19 condition and their relationship with cognition.Scientific reports · 2025Trial
- Brain Volumetric Changes Post-COVID-19: A Systematic Review.Brain sciences · 2025Review
- First episode of psychiatric and neuropsychiatric disease among patients infected with COVID-19: A scoping review.PCN reports : psychiatry and clinical neurosciences · 2025Review
- Acute and long-term effects of COVID-19 on brain and mental health: A narrative review.Brain, behavior, and immunity · 2025Review
- Article
- Functional magnetic resonance imaging of depression: a bibliometrics and meta-analysis.Annals of general psychiatry · 2024Article
- Glymphatic system dysfunction in recovered patients with mild COVID-19: A DTI-ALPS study.iScience · 2024Article
- Microstructural brain abnormalities, fatigue, and cognitive dysfunction after mild COVID-19.Scientific reports · 2024Article
- Anxiety in post-covid-19 syndrome - prevalence, mechanisms and treatment.Neuroscience applied · 2024Review
- On the merits and potential of advanced neuroimaging techniques in COVID-19: A scoping review.NeuroImage. Clinical · 2024Article
- Multimodal neuroimaging in Long-COVID and its correlates with cognition 1.8 years after SARS-CoV-2 infection: a cross-sectional study of theFrontiers in neurology · 2024Article
- Altered brain function and structure pre- and post- COVID-19 infection: a longitudinal study.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2024Article
- Microbes and Mental Illness: Past, Present, and Future.Healthcare (Basel, Switzerland) · 2023Review
- Persistent post-COVID headache is associated with suppression of scale-free functional brain dynamics in non-hospitalized individuals.Brain and behavior · 2023Observational
- COGNITIVE, NEUROLOGICAL, NEUROPSYCHOLOGICAL AND NEUROPSYCHIATRIC ALTERATIONS IN POST-COVID-19 PATIENTS.Actas espanolas de psiquiatria · 2023Article
- Effects of post-acute COVID-19 syndrome on the functional brain networks of non-hospitalized individuals.Frontiers in neurology · 2023Article
- Regional Homogeneity of the Left Posterior Cingulate Gyrus May Be a Potential Imaging Biomarker of Manic Episodes in First-Episode, Drug-Naive Bipolar Disorder.Neuropsychiatric disease and treatment · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCOVID-19 is an infectious disease that has spread worldwide in 2020, causing a severe pandemic. In addition to respiratory symptoms, neuropsychiatric manifestations are commonly observed, including chronic fatigue, depression, and anxiety. The neural correlates of neuropsychiatric symptoms in COVID-19 are still largely unknown.
methodsA total of 79 patients with COVID-19 (COV) and 17 healthy controls (HC) underwent 3 T functional magnetic resonance imaging at rest, as well as structural imaging. Regional homogeneity (ReHo) was calculated. We also measured depressive symptoms with the Patient Health Questionnaire (PHQ-9), anxiety using the General Anxiety Disorder 7-item scale, and fatigue with the Multidimension Fatigue Inventory.
resultsIn comparison with HC, COV showed significantly higher depressive scores. Moreover, COV presented reduced ReHo in the left angular gyrus, the right superior/middle temporal gyrus and the left inferior temporal gyrus, and higher ReHo in the right hippocampus. No differences in gray matter were detected in these areas. Furthermore, we observed a negative correlation between ReHo in the left angular gyrus and PHQ-9 scores and a trend toward a positive correlation between ReHo in the right hippocampus and PHQ-9 scores. LIMITATIONS: Heterogeneity in the clinical presentation in COV, the different timing from the first positive molecular swab test to the MRI, and the cross-sectional design of the study limit the generalizability of our findings.
conclusionsOur results suggest that COVID-19 infection may contribute to depressive symptoms via a modulation of local functional connectivity in cortico-limbic circuits.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.